Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to earnings of$1.15 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this RNA interference drug developer would post a loss of $0.74 per share when it actually produced earnings of$0.56, delivering a surprise of 175.68%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.A ...